top of page

LATEST PROJECTS

“True liberty, by protecting the exertions of talents and industry, and securing to them their justly acquired fruits, tends more powerfully than any other cause to augment the mass of national wealth.”

— Alexander Hamilton, Defense of the Funding System

GRAPHIC
What They’re Saying

These are excerpts from public comments that oppose the Biden administration's draft guidance for Bayh-Dole march-in to forcibly relicense patents if an agency disagrees with the product price.

COMMENT LETTER
Price-Based March-In

NIST proposes the single most destructive policy conceivable: Injecting pricing into Bayh-Dole march-in, which has never been used and has no statutory grounds for product price. NIST must withdraw this dangerous framework.

COALITION LETTER
House Death Tax Repeal Bill

CPR commends Reps. Randy Feenstra (R-IA) and Sanford Bishop (D-GA) on introducing the Death Tax Repeal Act in the House. It has over 160 original cosponsors, and the supporting coalition letter has nearly 160 signers.

COMMENT LETTER
WIPO’s Red Tape on Patenting

WIPO seeks to impose new burdens on inventors. They break with decades of precedent, cause legal uncertainties, and undermine the innovation that relies on the global patent system.

COALITION LETTER
Restore Progrowth Tax Incentives

Congress should improve economic conditions with a fiscally responsible, broad-based tax package that encourages more investment in the American economy, including bonus depreciation, R&D deductions and EBITDA depreciation.

COALITION LETTER
Extend NIST Comment Period

The potential changes to Bayh-Dole’s march-in would have far-reaching effects on innovation. We request 90 more days to comment, to ensure full analysis of the proposal's impact.

LETTER
Defense of Property Rights Act

H.R. 6758 enables property owners to hold the federal government accountable for takings. Its more efficient, uniform process helps citizens to secure their Fifth Amendment rights.

COALITION LETTER
95% Tax Risks Harm

Government price controls will lead to minimal production, scarcity of the medicine, and eventually government rationing. The 95% tax will massively increase the price of the medicine and distort our health system and economy.

COMMENT LETTER
Joint Standards Initiative

If PTO is to achieve its goal of fostering U.S. involvement and leadership in standards development in the most important technological areas, then policies and regulatory action must accord with private property rights and free markets.  Otherwise, the initiative is destined to fall short of fostering U.S. innovation, standards development, SEPs and licensing.

COALITION LETTER
End IRA Prescription Drug Price Controls

Given the well-documented destructive history of price controls and the law’s expansion of government power over our health-care system, we, the undersigned organizations, strongly urge Congress to repeal the prescription drug prices controls found within the Inflation Reduction Act.

STATEMENT
USITC’s TRIPS report

The International Trade Commission’s thorough investigation provides the U.S. Trade Representative no basis for expanding the TRIPS waiver to COVID diagnostics and therapeutics.

STATEMENT
WOTUS Reform in FY24 Energy & Water

CPR strongly commends the Waters of the United States provision in the U.S. House’s FY24 Energy and Water appropriations. H.R. 4394 blocks EPA’s latest attempt at regulatory takings of private land.

DOCUMENTARY SCREENING
CPR Cohosts “Innovation Race” Film Showing

This award-winning film gave Capitol Hill attendees a focus on ingenuity, property rights, and the stakes of global leadership in emerging technologies. CPR, the Inventor's Project and Tea Party Patriots Action cosponsored, Rep. Bill Posey gave remarks about U.S.-China competitiveness and innovation’s and IP's critical roles.

COALITION DOCUMENT
New IP Principles by U.S. Chamber’s GIPC

The U.S. Chamber Global Innovation Policy Center’s IP principles describe how "a renewed and principled approach to intellectual property is key to unlocking America’s full innovative and creative potential in the 21st century.” CPR’s James Edwards ranks among the signatories.

LETTER
Patent Eligibility Restoration Act

S. 2140 would fully invalidate all judicially created exceptions to patent eligibility. It would restore the congressionally intentional breadth of the section 101 threshold question as to patent-eligible subject matter, including of a “useful process.”

COMMENT LETTER
NIH Tech Transfer

CPR cautions the agency against new changes which could have deleterious effects on patients and give competitors like China an edge in the technology sphere.

LETTER
PAHPA Price Controls

These “reasonable pricing” requirements would apply to marketable drug, biologic, or other medical technology that stems from federal research funding from the Centers for Disease Control (CDC) and BARDA. These strictures are virtually guaranteed to reduce innovation and fail to achieve the stated goal.

LETTER
PAHPA Rx Pricing

The Senate HELP Committee’s Pandemic and All-Hazards Preparedness Act reauthorization contains “reasonable pricing” provisions of grave concern. These would repeat the National Institutes of Health’s tried-and-failed experience of the 1990s.

LETTER
Support of PREVAIL Act

The PREVAIL Act would secure private property rights to inventions and give quiet title, which is crucial for commercialization and investment. That will boost the United States’s competitive edge in emerging technologies important to our economic and national security.

COMMENT LETTER
Changes Before PTAB

To be successful, any rule must ensure that patent owners have quiet title to their intellectual property, the exclusivity the U.S. Constitution promises to secure, and the ability to enforce their legal rights against patent infringers.

AMICUS BRIEF
Centripetal Networks v. Cisco

IP rights only work when they can be enforced through judicial process with meaningful remedy. The appellate ruling undermines confidence in the judicial process and harms innovators that confront willful infringement committed by larger competitors.

STATEMENT
Senate and House Hearings on PTAB

PTAB endangers America’s inventors whose commercial success is vital to our global leadership in innovation. Beleaguered inventors face tremendous threats, due to PTAB and its most frequent users, Big Tech and Chinese national champions.

AMICUS BRIEF
Palo Alto Networks v. Centripetal Networks

CPR strongly supports Centripetal Networks’s request for rehearing and POP review of the decision instituting IPR. Centripetal won in Article III court. Palo Alto is gaming the system to get leverage in separate litigation involving different patents.

AMICUS BRIEF
CPR Joins Amicus Brief in Sackett v. EPA

Amici urge the Supreme Court to adopt a "continuous surface connection" standard in WOTUS wetlands cases under the Clean Water Act. This will reduce regulatory takings and Fifth Amendment violations.

COMMENT LETTER
Comments on Draft SEP Policy Statement

DOJ's draft statement on standards-essential patents falls short of achieving the proper balance, neutrality, and respect for both innovators and implementers in their complementary roles related to innovation, SEPs, and licensing. 

LETTER
The Restoring America's Leadership in Innovation Act

H.R. 5874, the Restoring America’s Leadership in Innovation Act, would strengthen private property rights in one’s inventions and discoveries. The bill would go a long way toward reversing the antipatent onslaught of recent years. RALIA would counter the sustained assault by courts, Congress, the Administrative State, and patent-infringer interests.

VIDEO
CPR Briefing on Property Rights

This webinar, hosted by Conservatives for Property Rights, highlights how ownership rights relate to private property of every type. Keynote Speaker: Rep. Dan Newhouse (R-Wash.), House Chairman, Congressional Western Caucus.

IMG_0969.jpeg

CPAC panel on patent property rights with, L-R, CPR Executive Director Jim Edwards, CPR member-Tea Party Patriots' Jenny Beth Martin and USPTO Director Andrei Iancu.

Statements of Principles

bottom of page